Abstract
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are the most widely consumed pharmacological agents in endurance sport, with reported prevalence of 14.8%–88% and consumption dominated by prophylactic rather than therapeutic intent despite three meta‐analyses demonstrating no ergogenic effect. This use is sustained by a decision architecture in which pain is reframed as a controllable barrier to performance, prophylactic dosing is normalized within the training group, and renal risk is systematically underestimated: Among IRONMAN triathletes, only 27% were aware of it. This narrative review reframes the safety problem around the kidney. During prolonged high‐intensity exercise, three stressors converge: sympathetic renal vasoconstriction, progressive dehydration activating the renin–angiotensin–aldosterone system, and NSAID‐mediated prostaglandin inhibition, removing the compensatory vasodilatory safety net. This sport‐specific convergent renal insult differs structurally from the clinical triple whammy because the first two stressors are intrinsic to the activity itself. The clinical manifestation appears intensity‐ and duration‐dependent: Ibuprofen increased acute kidney injury rates from 34% to 52% during an 80‐km ultramarathon stage (NNH 5.5; not statistically significant) but did not amplify biomarker responses during one hour of moderate running. Whether repeated transient insults accumulate into chronic kidney disease, as established for occupational heat‐stress nephropathy and for hospital‐documented AKI, remains the central unanswered question for habitual athletic NSAID users. Among the guideline documents reviewed, none currently addresses habitual over‐the‐counter NSAID use under exercise‐induced renal stress in healthy athletes. The epidemiology and decision architecture of repeated exposure, the renal evidence base, the cumulative‐exposure question, and the gap in current guidance together define future research needs for endurance‐sport analgesic pharmacovigilance.
Keywords: acute kidney injury, chronic kidney disease, community pharmacy, endurance sport, guideline gap, NSAID, self-medication
Key Points
-
•
What is already known
-
◦
NSAID consumption in endurance sport is widespread (reported prevalence of 14.8%–88%), predominantly prophylactic, and continues despite three meta‐analyses demonstrating no ergogenic effect.
-
◦
Ibuprofen increased acute kidney injury incidence from 34% to 52% during an 80‐km ultramarathon stage (NNH 5.5; not statistically significant) but did not amplify biomarker responses during one hour of moderate‐intensity exercise.
-
◦
Community pharmacy counseling for over‐the‐counter analgesics underperforms in actual practice, with information provision observed in only 3%–34% of encounters.
-
•
What this review adds
-
◦
A sport‐specific convergent renal insult model integrating sympathetic vasoconstriction, progressive dehydration, and NSAID‐mediated prostaglandin inhibition explains why the renal risk of exercise‐associated NSAID use is intensity‐ and duration‐dependent.
-
◦
Transient exercise‐induced biomarker elevations are the dose‐dependent normative physiological response to prolonged exercise; whether repeated transient insults accumulate into chronic kidney disease, as established for occupational heat‐stress nephropathy, remains empirically untested in habitual athletic users.
-
◦
Among the nephrology and sports medicine guidelines reviewed, none currently addresses habitual over‐the‐counter NSAID use during exercise‐induced renal stress in healthy athletes; this gap in current guidance identifies three future research needs for the field.
1. Background
Translational Sports Medicine bridges mechanistic research and applied insight into human exercise, with direct relevance to the diagnosis, treatment, performance, and prevention of sports‐related disease and injury. The analgesic self‐medication landscape in endurance sport sits squarely on this bridge: mechanistic evidence from pharmacology, nephrology, and exercise physiology accumulates on one side, while the behavior of the self‐medicating athlete, the counseling encounter at the community pharmacy, and the absence of sport‐specific guideline coverage remain on the other. This review attempts to carry the mechanistic evidence forward.
Pain in endurance sport is simultaneously an inevitable consequence of training, a perceived barrier to performance, and a culturally valorized marker of athletic identity. The ethos of “no pain, no gain” coexists paradoxically with widespread pharmacological suppression of the very pain signals it celebrates. Nonsteroidal anti‐inflammatory drugs (NSAIDs) are the agents most frequently used. Their risk profile under exercise, however, is not the resting‐state profile that informed regulatory approval: The kidney operates at the margin of its compensatory reserve during prolonged exertion.
This review synthesizes evidence at the intersection of sports medicine, pharmacology, and nephrology with three objectives: describe the epidemiology of NSAID self‐medication and the decision architecture that sustains it; propose a sport‐specific convergent renal insult model that explains why NSAID risk is intensity‐ and duration‐dependent; and identify the future research needs required to close the gap between cross‐sectional evidence and the longitudinal question of whether habitual use across a multidecade athletic career imposes a cumulative renal cost invisible at any single assessment.
To orient the reader, the organizing construct of this review is introduced here: the exercise‐induced renal vulnerability model, whose mechanistic core is the convergent renal insult (Figure 1). The sections that follow build progressively toward this model: epidemiology and behavior explain why athletes are repeatedly exposed, pharmacology and renal physiology explain how the stressors converge, and the clinical evidence tests the resulting intensity‐ and duration‐dependentpredictions.
FIGURE 1.

The sport‐specific convergent renal insult model. (A) Three independently documented mechanisms, sympathetic renal vasoconstriction (intensity‐dependent), progressive dehydration (renin–angiotensin–aldosterone system activation), and NSAID‐mediated prostaglandin inhibition (COX blockade), converge on a central renal vulnerability zone. The convergence itself is the author’s construct; the individual mechanisms are established physiology. (B) Empirical data points from published studies plotted against exercise duration, with renal risk on the vertical axis: 1 hour of moderate‐intensity running at 60% VO2 peak (no amplification; Specht et al. [27]); marathon (four to five hours, nine hospitalizations including three for transient renal failure; Küster et al. [6]); IRONMAN (eight to seventeen hours, fivefold hyponatremia risk; Wharam et al. [28]); 80‐km stage of a multistage ultramarathon (number needed to harm 5.5 for acute kidney injury; Lipman et al. [7]). The dashed threshold curve connecting these points is a hypothesized dose–response relationship proposed by the author rather than a statistical model. It is not calibrated against outcome data and should be read as a hypothesis‐generating construct. The figure as a whole presents the exercise‐induced renal vulnerability model; Panel A depicts its mechanistic core, the convergent renal insult.
2. Methods
This is a narrative review; no PRISMA protocol was registered. Evidence was identified between January and March 2026 through structured searches of PubMed, SPORTDiscus, the Cochrane Library, and Google Scholar, supplemented by citation tracking of key systematic reviews. Search terms combined NSAID, analgesic, self‐medication, endurance sport, triathlon, marathon, ultramarathon, cross‐country skiing, acute and chronic kidney injury, cystatin C, heat‐stress nephropathy, and pharmacist counseling. Inclusion was guided by relevance and mechanistic or clinical insight rather than formal eligibility criteria. Quantitative estimates are reported as cited from primary studies and are not the product of pooled meta‐analytic synthesis within this review. Reporting followed the Scale for the Assessment of Narrative Review Articles (SANRA). Searches were restricted to English‐ and German‐language publications with no date restriction, and original studies, systematic reviews, and clinical practice guidelines were considered. Guideline documents from Kidney Disease: Improving Global Outcomes (KDIGO), the American College of Sports Medicine (ACSM), the International Olympic Committee (IOC), the German College of General Practitioners and Family Physicians and the German Society of Nephrology (DEGAM/DGfN), the Association of the Scientific Medical Societies in Germany (AWMF), and the Federal Union of German Associations of Pharmacists (ABDA) were appraised purposively, not through a systematic guideline search, for their treatment of the NSAID–exercise–hydration intersection.
No comprehensive database search in the systematic‐review sense was performed, and the strategy is documented here for transparency rather than for exact reproducibility. An illustrative core string, run in PubMed and adapted for the remaining databases, combined (NSAID∗ OR “anti‐inflammatory agents, non‐steroidal” OR ibuprofen OR diclofenac OR analgesic∗) AND (endurance OR marathon OR ultramarathon OR triathlon OR “cross‐country skiing” OR exercise) AND (kidney OR renal OR “acute kidney injury” OR “cystatin C” OR nephropathy OR dehydration). Records were eligible if they reported prevalence or patterns of analgesic self‐medication in athletes, organ‐specific effects of NSAIDs under exercise, the renal physiology of prolonged exercise, or guideline positions on NSAID use. Records were excluded if they were published in a language other than English or German, were animal or in vitro studies without a stated translational argument, addressed exclusively pediatric or clinically ill populations without an exercise component, or were conference abstracts, editorials, or letters without primary data. Screening and eligibility assessment were performed by a single author without duplicate screening and without a formal record count, so the yield reported here cannot be reproduced exactly.
3. NSAID Use in Endurance Sport: Prevalence and Consumption Patterns
NSAID consumption in endurance sport is widespread, predominantly prophylactic, and pharmacologically uninformed. Reported prevalence ranges from 14.8% in Norwegian doping‐control data [1] to 88% in scoping reviews of ultra‐endurance running [2], with methodological heterogeneity precluding formal meta‐analysis [3]. Prevalence estimates vary systematically by performance tier [4], sex [5], discipline [1], and temporal context: training‐phase use exceeds competition‐day use in Norwegian VO2max endurance sports, including cross‐country skiing (71.6% of out‐of‐competition vs. 57.6% of in‐competition doping control forms listing at least one pharmaceutical, p < 0.001 [1]). The Bonn Marathon study [6] documented that 49.4% of 3913 runners consumed analgesics before the race, with 43% of ibuprofen users self‐escalating to ≥ 800 mg, effectively prescription‐level regimens without medical oversight, and a fivefold higher adverse‐event rate in the analgesic cohort, including nine hospitalizations. Lipman et al. [7], in the only randomized field trial, found acute kidney injury in 52% of runners on ibuprofen versus 34% on placebo during the 80‐km stage of a 250‐km multistage ultramarathon (odds ratio 2.1, 95% CI 0.9–5.1; NNH 5.5). Table 1 summarizes the principal prevalence studies.
TABLE 1.
Selected prevalence studies of NSAID and analgesic use in endurance sport.
| Study [Ref] | Population | n | Prevalence | Key finding |
|---|---|---|---|---|
| Gorski et al. 2011 [8] | IRONMAN triathletes | 327 | 59.9%/47.4% race‐day | 62.4% cited pain prevention; 27% knew renal risk |
| Küster et al. 2013 [6] | Bonn marathon | 3913 | 49.4% prerace | 5× adverse‐event rate; 43% took ≥ 800 mg ibuprofen |
| Dietz et al. 2016 [5] | Competitive triathletes | 2997 | 31% prophylactic | Doping prevalence 20.4% in users vs. 12.4% in non‐users |
| Gjelstad et al. 2023 [1] | Norwegian athletes (DCFs) | 10,418 | 14.8% NSAID (all sports); 71.7% any pharmaceutical (XC‐ski) | OOC use exceeds IC use |
| Robach et al. 2024 [9] | Ultramarathon (urine) | 412 | 49.8% any substance | Objective > self‐report |
| Cole et al. 2025 [4] | Ultra‐endurance runners | 167 | 53% | Tier 5 strategic; Tiers 1–4 reactive |
| Fitzpatrick et al. 2025 [10] | Recent Olympic/Paralympic Games | NR | NR | NSAIDs and paracetamol are most commonly dispensed at Games pharmacies |
Note: Fitzpatrick et al. [10] is a review; the Olympic and Paralympic pharmacy data it summarizes are reported without a denominator, so neither a sample size nor a user‐level prevalence estimate can be extracted.
Abbreviations: DCF, doping control form; IC, in‐competition; NR, not reported; OOC, out‐of‐competition.
Four consumption phenotypes are proposed as a framework for future prospective research: prophylactic competition use (acute, planned single dose before races, dominant in 31%–62% of competitive triathletes [5, 8]); reactive episodic treatment (2–5 days during pain flares, characteristic of recreational ultra‐runners [4]); habitual chronic use (daily or near‐daily over weeks to months, documented in 50% of collegiate athletes [11]); and subtherapeutic microdosing (low‐dose routine consumption of uncertain pharmacological significance). These phenotypes have fundamentally different pharmacological implications: Prophylactic use carries acute renal and gastrointestinal risk but minimal cumulative burden, whereas habitual use generates sustained prostaglandin suppression, cumulative organ toxicity, and the greatest potential for training‐adaptation impairment. No existing study has prospectively quantified the distribution of these phenotypes in an endurance‐sport population; Leyk et al. [3] explicitly identified this as a central evidence gap in the European literature.
4. Pharmacological Landscape: A Heterogeneous Class
NSAIDs share a common mechanism (inhibition of cyclooxygenase enzymes catalyzing the conversion of arachidonic acid to prostaglandins) but vary by orders of magnitude in COX‐isoform selectivity, potency, half‐life, and tissue distribution [12, 13]. COX‐1 is constitutive and maintains gastric mucosal protection, platelet aggregation, and renal perfusion. COX‐2 is inducibly expressed at sites of inflammation but is also constitutive in the kidney, particularly the macula densa and renal medulla, where it is upregulated during dehydration. Ibuprofen is COX‐1‐preferring; diclofenac is functionally COX‐2‐preferring (ratio ≈29; Mallinson et al. [14]; Warner et al. [15]); celecoxib and etoricoxib are highly COX‐2 selective. Paracetamol is often considered safer but can achieve up to 80% COX‐2 inhibition in a whole‐blood assay at 1 g under low‐peroxide conditions [16], and it cannot be assumed to spare the renal prostaglandin axis during exercise‐induced dehydration. Athletes frequently self‐escalate beyond OTC dose limits [6]. Table S1 provides the detailed pharmacological profile of analgesics relevant to endurance sport, and Figure S1 visualizes their COX‐selectivity (see also Supporting Information, sections S1 and S5).
5. From Pain to Pill: The Decision Architecture of Self‐Medication
The path from musculoskeletal pain to pharmaceutical action is mediated by cognitive appraisal, not pharmacological evaluation. Lazarus’ cognitive‐motivational‐relational theory [17, 18] frames the process: Primary appraisal assesses whether pain threatens a goal (a race, a training block, or athletic identity), and secondary appraisal identifies available coping resources. Self‐medication with over‐the‐counter analgesics emerges as the path of least resistance because the pharmacy is universally accessible and ibuprofen is culturally normalized. Melzer et al. [19] showed that situational opportunity (η2 = 0.24) and competitive worry (r = 0.33) predict analgesic use; Dietz et al. [5] reported that among competitive triathletes, self‐reported 12‐month doping prevalence was higher in athletes who also used analgesics (20.4%) than in non‐users (12.4%). NSAIDs themselves are not prohibited substances and are not classified as doping. The association suggests that NSAID self‐medication and doping may share underlying motivational drivers, such as competitive pressure and performance anxiety, rather than that NSAID use constitutes a form of doping.
Once pain is relieved, a neurobiological reinforcement mechanism activates. Navratilova et al. [20] showed that pain relief is an active reward engaging opioid signaling in the anterior cingulate cortex and dopamine release in the nucleus accumbens, the same mesolimbic circuitry engaged by food and addictive substances. Every episode in which ibuprofen alleviates pain before a run reinforces the behavior. Athletes dramatically underestimate NSAID risk: Cullen et al. [21] found patients rated NSAID risk at 2.1/10 versus 6.2/10 by professionals, and Mullan et al. [22] documented that roughly one‐third of OTC purchasers could not identify the maximum daily dose. Information sources are predominantly informal (Cole et al. [4]: 41% websites, 33% podcasts, 31% physicians). This combination transforms NSAID self‐medication from a knowledge problem into a behavioral one, with direct implications for intervention design (the full seven‐stage cause‐effect arc is presented as Figure S2).
6. Exercise‐Induced Renal Vulnerability: A Sport‐Specific Model
The renal safety profile of NSAIDs established in resting patients does not transfer to the exercising athlete. This review frames the problem at two levels: the broad exercise‐induced renal vulnerability model, which describes the overall predisposition of the exercising kidney, and its mechanistic core, the convergent renal insult, which specifies the three‐way convergence developed below (Figure 1). During prolonged endurance exercise, three stressors converge. First, sympathetic renal vasoconstriction: Poortmans [23] demonstrated that renal blood flow falls with exercise intensity, reaching as low as 25% of resting values during strenuous work, mediated by catecholamine‐driven constriction of renal arterioles. Compensatory prostaglandin synthesis (PGE2 and PGI2) maintains afferent arteriolar vasodilation under these conditions, preserving glomerular filtration despite rising sympathetic tone. Second, progressive dehydration: effective circulating volume declines through sweat loss and respiratory water loss, activating the renin–angiotensin–aldosterone system and increasing renal dependence on prostaglandin‐mediated vasodilation. Third, NSAID‐mediated prostaglandin inhibition: when an athlete consumes an NSAID before or during exercise, this compensatory vasodilatory safety net is removed precisely when the kidney is most dependent on it.
This sport‐specific convergent renal insult is not analogous to the clinical triple‐whammy of angiotensin‐converting enzyme inhibitors, diuretics, and NSAIDs in a resting patient [24, 25]. This interaction is explained by NSAIDs causing vasoconstriction of the afferent arterioles, while ACE inhibitors and angiotensin II receptor blockers (ARBs) induce vasodilation. These effects lower the glomerular filtration rate (GFR). Diuretics additionally cause hypovolemia. The exercise scenario involves two stressors intrinsic to the activity combined with one pharmacological agent, and both intrinsic stressors are progressive, intensity‐ and duration‐dependent, and not amenable to drug–drug interaction management. The clinical triple whammy is itself well characterized: In a nested case–control study of 78,379 community users of renin–angiotensin system inhibitors and/or diuretics, NSAID exposure raised acute kidney injury risk in both triple and dual combinations, with the absolute risk highest under triple therapy (number needed to harm 158 vs. over 300 for dual combinations) [26]. This sharpens the mechanistic contrast: in the clinical setting the afferent (NSAID), efferent (renin–angiotensin system inhibitor), and volume‐depletion (diuretic) hits are all pharmacological, whereas in endurance exercise two of the three stressors are intrinsic, progressive consequences of the activity itself. Figure 1 depicts the model and maps published empirical data onto the intensity‐duration axis.
The clinical manifestation is threshold‐dependent. Lipman et al. [7], in the only randomized field trial, found that ultramarathon runners randomized to ibuprofen 400 mg every 4 h during the 80‐km stage of a 250‐km multistage race developed acute kidney injury more often than those on placebo (52% vs. 34%; odds ratio 2.1, 95% CI 0.9–5.1; number needed to harm 5.5), a difference that did not reach statistical significance. At the other end of the intensity‐duration spectrum, Specht et al. [27] randomized 11 physically active individuals to 1 hour of running at 60% VO2peak in 35°C heat with ibuprofen 600 mg or placebo: Exercise itself increased all acute kidney injury biomarkers (IGFBP7•TIMP2, neutrophil gelatinase‐associated lipocalin, and cystatin C), but ibuprofen did not amplify this response, though proinflammatory interleukin‐8 did increase (p = 0.03). These two studies are consistent with a threshold: The convergence of stressors may require sustained high‐intensity or long‐duration exercise, as in ultramarathons or IRONMAN, to produce clinically manifest injury, whereas moderate exercise for shorter durations may not reach the pathological threshold. Fitzpatrick et al. [10] cite a pooled acute kidney injury odds ratio of 1.7 (95% CI 1.4–2.1) for current NSAID exposure in the general population, derived from a systematic review of 1,609,163 participants; the intensity‐ and duration‐adjusted magnitude in endurance athletes remains uncalibrated.
The threshold model is further supported by studies of the renal response to prolonged exercise without NSAID exposure. Poussel et al. [29] prospectively studied 55 finishers of a 120 km mountain ultramarathon without recent NSAID use: Classical RIFLE criteria identified 0% AKI at the finish line, while biomarker‐based definition using urinary NGAL/creatinine identified 12.5%. Estimated GFR via cystatin C significantly increased rather than decreased across the race, in contrast to creatinine‐based values, underscoring the superiority of cystatin C for assessing exercise‐associated renal function. Wołyniec et al. [30] provided within‐subject dose–response data: The same 16 runners completed both a 10 km and a 100 km race, with all urinary AKI biomarkers (NGAL, KIM‐1, and cystatin C) rising significantly after both events and a clear intensity gradient favoring the longer distance. Mansour et al. [31] documented that 82% of marathon finishers met at least AKIN stage 1 creatinine criteria, with injury biomarkers peaking immediately postrace and declining significantly within 24 h. Together, these studies establish transient biomarker‐level responses as the normative physiological consequence of prolonged exercise, with magnitude dose‐dependent on duration and intensity. Throughout this review, three categories are kept distinct and must not be conflated: transient, self‐resolving biomarker elevations that represent a normal physiological response to exertion; acute kidney injury defined by clinical or biomarker criteria; and the hypothesized long‐term risk of chronic kidney disease. A biomarker rise during exercise is not, in itself, evidence of clinically relevant kidney damage.
6.1. Cumulative Exposure and the Heat‐Stress Nephropathy Analog
Beyond acute exercise‐induced events, accumulating evidence links cumulative lifetime NSAID exposure to chronic kidney disease progression. Soliman et al. [32], in a meta‐analysis of 40 studies (n = 1,757,118), found long‐term NSAID use significantly increased both occurrence and progression of chronic kidney disease (pooled hazard ratio 1.50, 95% CI 1.31–1.70), with risk higher in individuals with pre‐existing CKD (HR 1.67) than in the general population (HR 1.31). The meta‐analysis did not identify a differential effect between COX‐1‐preferring and COX‐2‐selective agents, consistent with a class‐wide cumulative nephrotoxicity signal.
The conceptual bridge between transient exercise‐induced insult and long‐term chronic kidney disease has an important mechanistic precedent outside sport. Coca et al. [33] demonstrated in a meta‐analysis of 13 cohort studies that even mild, ostensibly reversible AKI episodes are associated with markedly elevated long‐term risk of CKD (pooled adjusted HR 8.8, 95% CI 3.1–25.5), end‐stage renal disease (HR 3.1), and mortality (HR 2.0), with a dose–response relationship between injury severity and subsequent disease risk. This nephrological principle, that repeated transient insults can accumulate into chronic structural disease, has been independently observed in occupational health. Glaser et al. [34] described heat‐stress nephropathy, an emergent CKD epidemic among sugarcane workers in Mesoamerica, Sri Lanka, and other hot agricultural regions, whose pathophysiology rests on the recurrent combination of heat, physical exertion, and inadequate hydration, each workday producing a reversible insult that cumulatively drives tubulointerstitial fibrosis and irreversible decline. The parallel to endurance athletes is offered as a mechanistic analogy rather than a direct equivalence, since the populations, exposure frequency, environmental conditions, and workload differ; habitual NSAID use would layer an additional pharmacological insult onto this substrate. Whether the occupational analog extends to endurance athletes remains empirically untested, but the mechanistic plausibility places habitual athletic users in a population of concern that current cross‐sectional safety data cannot characterize.
For the habitual consumption phenotype, these findings reframe the risk calculus. As a hypothetical high‐consumption scenario rather than the average pattern, an athlete who takes 400 mg ibuprofen before every long run (two to three times weekly) would accumulate 300–450 tablets per year, a cumulative exposure that, sustained over a 10–20‐year athletic career, places them in the upper exposure categories associated with accelerated GFR decline. This risk is invisible in cross‐sectional prevalence studies and undetectable by the athlete, as chronic kidney disease is typically asymptomatic until advanced stages.
7. Organ‐Specific Risks Beyond the Kidney
Although the renal axis carries the most sport‐specific risk, three additional organ systems warrant brief comment. Gastrointestinal: van Wijck et al. [35] demonstrated that ibuprofen approximately doubles plasma markers of small‐intestinal injury during cycling compared with exercise alone, with concomitant barrier disruption. Co‐prescribing a proton‐pump inhibitor addresses only the upper gastrointestinal tract (see Supporting Information, section S3.2). Cardiovascular: the Coxib and traditional NSAID Trialists’ Collaboration [36], pooling individual participant data from 754 trials (n > 350,000), quantified increased major vascular events (coxibs: RR 1.37; diclofenac: RR 1.41) and a doubling of heart‐failure hospitalizations across all classes, mediated by COX‐2–dependent renal sodium and water retention; naproxen uniquely did not significantly increase vascular events. Musculoskeletal: Trappe et al. [37] and Lilja et al. [38] showed that ibuprofen attenuates resistance‐training–induced muscle hypertrophy in young adults, yet Trappe et al. [39] found the opposite in older adults, and Mallinson et al. [14] demonstrated diclofenac‐augmented hypertrophy in trained young men (8.6% vs. 3.9%), indicating COX‐isoform–specific and age‐dependent effects that preclude class‐wide conclusions. For endurance athletes, indomethacin abolishes the running‐induced rise in patellar tendon collagen synthesis after a 36 km run [40], suggesting impaired connective‐tissue remodeling under habitual use.
The definitive meta‐analysis by Cornu et al. [41] of 23 randomized trials (n = 514) found no significant effect of NSAIDs on strength, endurance, or power outcomes (effect sizes d = −0.03 to +0.08). Paracetamol shows a small but significant effect in time‐to‐exhaustion tests (d = 0.19; Grgic and Mikulic [42]), likely mediated through central pain modulation. NSAID safety established in resting populations does not transfer cleanly to the exercising athlete, and risk communication requires agent‐specific framing.
8. The Guideline Gap at the Nephrology–Sports Medicine Intersection
A structured review of guideline documents reveals a gap in current guidance at the intersection of NSAID pharmacovigilance, exercise‐induced dehydration, and analgesic use in healthy athletes. The KDIGO guidelines for CKD [43, 44] and AKI [45] address NSAID nephrotoxicity in patients with established renal disease, including explicit “sick day rules” recommending discontinuation of NSAIDs during reduced fluid intake. The most recent German S3 Leitlinie on CKD in primary care [46] lists NSAIDs among the medications requiring special caution in CKD. None of these documents extends its scope to healthy athletes under exercise‐induced renal stress. The ACSM Position Stand on fluid replacement [47] provides detailed hydration recommendations but does not address pharmacological interactions. The IOC Consensus Statement on Pain Management [48] addresses NSAID use for acute injury pain but not prophylactic consumption or interaction with dehydration. Among the guideline documents reviewed, none addresses the specific scenario of habitual OTC NSAID use under exercise‐induced renal stress in healthy athletes. Table 2 summarizes the coverage matrix.
TABLE 2.
Coverage matrix of existing guidelines against the endurance athlete’s pain‐management context.
| Domain | KDIGO 2012/2013/2024 [43–45] | DEGAM/DGfN S3 2024 [46] | ACSM fluid 2007 [47] | IOC 2017 [48] |
|---|---|---|---|---|
| Exercise‐altered renal pharmacokinetics | Not addressed | Not addressed | Not addressed | Mentioned (general) |
| NSAID use under exercise‐induced dehydration | Not addressed | Not addressed (CKD focus) | Not addressed | General warning |
| Prophylactic/habitual use in healthy athletes | Not addressed | Not applicable (CKD focus) | Not addressed | Discouraged |
| NSAID nephrotoxicity in patients with renal impairment | Addressed (sick‐day rules, stewardship) | Addressed (NSAIDs listed among medications requiring caution) | Not addressed | Not primary focus |
| OTC self‐medication pathway | Not addressed | Not primary focus | Not addressed | Not primary focus |
| Pharmacist counseling role | Not addressed | Mentioned (general) | Not addressed | Not addressed |
Note: Category definitions. Addressed: the document contains an explicit recommendation or risk statement directed at the domain. General warning: the document warns about the drug class or the risk in general terms without specifying the athlete or exercise context. Discouraged: the document advises against the practice without stating conditions, thresholds, or monitoring guidance. Mentioned (general): The domain appears in the text without an accompanying recommendation or risk statement. Not primary focus: The domain lies outside the document’s stated scope but is touched upon incidentally. Not applicable: The domain lies outside the document’s target population by definition. Not addressed: No statement on the domain was identified in the document reviewed. Categories were assigned by a single author on a full reading of each document; no second rater was involved, and no formal agreement statistic was calculated.
Abbreviations: ACSM, American College of Sports Medicine; CKD, chronic kidney disease; DEGAM, Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin; DGfN, Deutsche Gesellschaft für Nephrologie; IOC, International Olympic Committee; KDIGO, Kidney Disease: Improving Global Outcomes; OTC, over‐the‐counter.
This gap in current guidance is itself a research‐relevant finding. It limits the ability of pharmacists, sports physicians, and athletes to make evidence‐informed decisions, and it frames the future research needs outlined below as directly consequential for future guideline development. The guidelines summarized in Table 2 were selected purposively as the most authoritative documents governing renal safety (KDIGO), sports‐medicine pain and hydration practice (IOC, ACSM), and German primary‐care and pharmacy practice (DEGAM/DGfN, ABDA); this appraisal is not a systematic guideline review, and a rating of “Not addressed” should be read accordingly.
9. The Community Pharmacist as an Unrealized Checkpoint
In systems such as the German one, every OTC NSAID transaction passes through a trained pharmacist, making the pharmacy the last professional checkpoint before an athlete takes ibuprofen into a marathon. The counseling opportunity is rarely actualized. Seiberth et al. [49] combined self‐report from 1068 pharmaceutical staff with nonparticipant observation: Information‐gathering parameters were reported to be addressed in ≥ 70% of consultations but observed in only 8%–63%, and information provision in only 3%–34% of encounters, with “lack of patient’s interest” (84%) as the most frequently cited barrier. Meta‐analytic evidence supports the efficacy of pharmacist interventions: Kelly et al. [50] demonstrated reduced adverse drug events (RR 0.86, NNT 33) across 15 randomized trials (14 contributing adverse‐drug‐event data). Proof of concept that structured review of high‐risk NSAID prescribing changes hard outcomes comes from the Data‐driven Quality Improvement in Primary Care (DQIP) cluster‐randomized trial: a complex intervention combining pharmacist‐led educational outreach, informatics, and incentives reduced targeted high‐risk NSAID and antiplatelet prescribing (adjusted odds ratio 0.63) and related emergency admissions, with the effect sustained after incentives ceased [51]. Athletes themselves express receptivity: 59% would modify NSAID use if better educated [3]. The ABDA Arbeitshilfe for headache self‐medication [52] provides a template that can be readily extended into a sport‐specific module covering exercise timing, hydration, and NSAID risk (Figure 2).
FIGURE 2.

Sport‐specific clinical decision algorithm for pain management in endurance athletes: differential triage of traumatic versus nontraumatic pain, exercise‐based rehabilitation as first‐line management, diagnosis‐specific NSAID indication (bursitis, osteoarthritis per NICE NG226, tendinopathy), and the community‐pharmacist checkpoint as the terminal node. Diagnosis‐specific branches are grounded in evidence cited in the main text; the integrated algorithm and the pharmacist checkpoint are the author’s proposal.
10. Future Research Needs
The renal research agenda for endurance sport has been framed, but not answered, for nearly a decade. Hoffman and Weiss [53], writing in the Clinical Journal of Sport Medicine, posed the question directly: “Does acute kidney injury from an ultramarathon increase the risk for greater subsequent injury?” They found no evidence that a prior episode worsened the response to a subsequent race, but whether repeated episodes carry long‐term consequences remained open; the absence of empirical progress on that question since defines the central gap identified by this review. Three interlocking priorities emerge.
10.1. Priority 1: Calibrating the Intensity–Duration Threshold
The renal safety evidence rests on a single field randomized controlled trial at one extreme of the exercise spectrum [7] and a single negative laboratory study at the other [27]. The threshold for clinically significant renal injury during NSAID use is undefined for the most common endurance event formats (Olympic‐distance triathlon, marathon, half‐marathon, and long‐format cross‐country skiing). Calibration requires controlled laboratory work using cystatin C–based markers that avoid the exercise‐induced creatinine artifact [29, 30]. Hydration must be controlled as an independent determinant: Juett et al. [54] recently demonstrated that 24 hours of severe fluid restriction alone significantly elevates urinary KIM‐1 without any exercise stimulus. A multicenter collaborative effort will likely be required to characterize the threshold across the range of event formats relevant to public health.
10.2. Priority 2: Quantifying Cumulative Lifetime Exposure
The hospital‐based cumulative‐exposure literature [33] and the occupational heat‐stress nephropathy literature [34] together establish a biologically plausible pathway by which repeated transient exercise‐associated renal insults, compounded by habitual NSAID use, could accumulate into chronic kidney disease over a multidecade athletic career. This pathway has never been tested empirically in endurance athletes. Addressing it requires prospective longitudinal cohorts, ideally with retrospective reconstruction of cumulative NSAID exposure paired with long‐term renal follow‐up, and is therefore most plausibly pursued through existing masters‐athlete registries and sport‐federation medical databases rather than through new ab initio cohort construction.
10.3. Priority 3: Prospective Characterization of Self‐Medication Patterns
All existing prevalence data are cross‐sectional. No study has prospectively quantified the four consumption phenotypes proposed above, the relationship between training‐load fluctuations and pharmaceutical decision‐making, or the within‐subject variability of NSAID use over weeks to months. Leyk et al. [3] identified this as the critical evidence gap in the European literature. Prospective diary‐based designs, paired with structured pharmacist‐counseling interventions in randomized or stepped‐wedge formats, would simultaneously address the descriptive gap and provide proof‐of‐concept evidence for a sport‐specific module of the existing ABDA counseling framework. Inclusion criteria should be broad enough to encompass the full spectrum of pain indications driving consumption, including menstrual and headache‐related use, which prevalence studies document but rarely disaggregate [4].
These three priorities are complementary rather than dependent. They are most plausibly pursued by independent research groups with independent cohorts and are best advanced when their findings are integrated into future updates of nephrology guidelines (KDIGO), sports medicine consensus statements (IOC, ACSM), and pharmacy self‐medication counseling frameworks (ABDA and equivalents).
11. Limitations
Several limitations qualify this synthesis. Some of the cited mechanistic studies had small sample sizes (n = 11–15), limiting power for small‐to‐medium effects. As a narrative review, this synthesis does not apply formal risk‐of‐bias assessment or quantitative pooling; evidence selection reflects the author’s judgment informed by expertise in pharmacy and sport science. Several further limitations warrant emphasis: literature was selected at the author’s discretion without a formal risk‐of‐bias instrument, introducing potential selection bias; reliance on the published record carries a risk of publication bias; extrapolation from clinical and occupational populations to otherwise healthy athletes is inherently uncertain; and the guideline appraisal was purposive rather than systematic, so any absence of coverage should be read as not identified among the documents reviewed rather than as definitive absence. Finally, the four consumption phenotypes proposed here constitute a conceptual framework that has not been prospectively validated.
12. Perspectives
The convergent renal insult model suggests where nephrology, occupational health, and sports medicine may usefully converge in their guidance. We encourage nephrology working groups (KDIGO) to consider extending existing NSAID recommendations beyond patients with established CKD to include the healthy athlete under sustained exercise‐induced renal stress. We invite sports medicine bodies (IOC, ACSM) to consider incorporating exercise‐specific pharmacological guidance into their pain‐management and fluid‐replacement frameworks, in recognition that resting‐state safety does not transfer cleanly to the exercising athlete. We similarly encourage community pharmacy organizations (ABDA and equivalents) to explore extending their established counseling frameworks with a sport‐specific module covering exercise timing, hydration, event duration, and cumulative‐exposure assessment at the point of sale (a candidate decision algorithm is shown in Figure 2). The future research needs outlined above are prerequisites for informed guideline development: until the intensity‐duration threshold is calibrated, cumulative lifetime exposure quantified, and self‐medication patterns prospectively characterized, guidance will remain reliant on extrapolation. This synthesis is offered as the conceptual foundation for that programmatic work and as a direct response to the question Hoffman and Weiss posed nearly a decade ago.
Nomenclature
- η 2
Partial eta squared
- 4‐MAA
4‐Methylaminoantipyrine
- ABDA
Bundesvereinigung Deutscher Apothekerverbände, Federal Union of German Associations of Pharmacists
- ACE
Angiotensin‐converting enzyme
- ACSM
American College of Sports Medicine
- AI
Artificial intelligence
- AKI
Acute kidney injury
- AM404
N‐Arachidonoylphenolamin
- ARB
Angiotensin II receptor blocker
- ASA, ASS
Acetylsalicylic acid
- ATC
Anatomical Therapeutic Chemical classification
- AWMF
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Working Group of Scientific Medical Societies
- BÄK
Bundesärztekammer, German Medical Association
- CI
Confidence interval
- CKD
Chronic kidney disease
- COX
Cyclooxygenase
- CV
Cardiovascular
- CYP2E1
Cytochrome P450 2E1
- d
Cohen’s d
- DCF
Doping control form
- DE
Deutschland, Germany
- DGSP
Deutsche Gesellschaft für Sportmedizin und Prävention, German Society for Sports Medicine and Prevention
- DGOU
Deutsche Gesellschaft für Orthopädie und Unfallchirurgie, German Society for Orthopedics and Trauma Surgery
- DILI
Drug‐induced liver injury
- DOMS
Delayed‐onset muscle soreness
- EMA
European Medicines Agency
- ES
Effect size
- FIMS
Fédération Internationale de Médecine du Sport, International Federation of Sports Medicine
- GFR
Glomerular filtration rate
- ΔeGFR
Change in estimated glomerular filtration rate
- GI
Gastrointestinal
- H+/K+‐ATPase
Hydrogen/potassium‐exchanging adenosine 5′‐triphosphatase
- HCP
Healthcare professional
- HR
Hazard ratio
- I 2
Impact of heterogeneity
- I‐FABP
Intestinal‐fatty acid binding protein
- IL‐8
Interleukin‐8
- IBU
Ibuprofen
- IC (1)
In competition
- IC (2)
Inhibitory concentration
- IGFBP7•TIMP2
Tissue inhibitor of metalloproteinases‐2 and insulin‐like growth factor‐binding Protein 7
- INN
International Nonproprietary Name
- IOC
International Olympic Committee
- KBV
Kassenärztliche Bundesvereinigung, National Association of Statutory Health Insurance Physicians
- KDIGO
Kidney Disease: Improving Global Outcomes
- MCID
Minimal clinically important difference
- MPS
Muscle protein synthesis
- MVC
Maximum voluntary contraction force
- NAPQI
N‐Acetyl‐p‐benzoquinone imine
- NGAL
Neutrophil gelatinase‐associated lipocalin
- NICE
National Institute for Health and Care Excellence
- NNH
Number needed to harm
- NNT
Number needed to treat
- NSAIDs
Non‐steroidal anti‐inflammatory drugs
- NVL
Nationale Versorgungs‐Leitlinie, National Care Guideline
- OA
Osteoarthritis
- OOC
Out of competition
- OR
Odds ratio
- OTC
Over‐the‐counter
- p
Probability value
- PG
Prostaglandin
- PGE2
Prostaglandin E2
- PGI2
prostaglandin I2, prostacyclin
- P1NP
Procollagen Type 1 N‐terminal propeptide
- pKa
Acid dissociation constant
- RAAS
Renin–angiotensin–aldosterone system
- RCT
Randomized clinical trial
- RKI
Robert Koch Institute
- PPI
Proton pump inhibitor
- PRISMA
Preferred Reporting Items for Systematic Reviews and Meta‐Analyses
- RR
Relative risk, risk ratio
- Rx
Rezeptpflichtig, prescription‐only
- S2k
Systematik 2. Stufe konsensbasierte Leitlinie, Systematic approach, level 2, consensus‐based guideline
- S3
Systematik Stufe 3 evidenzbasierte Leitlinie, Systematic approach level 3 evidence‐based guideline
- T1/2
Half‐life time
- TRPV1
Transient receptor potential vanilloid 1
- TTE
Time to exhaustion
- VAS
Visual Analog Scale
- VISA‐A
Victorian Institute of Sport Assessment‐Achilles
- VO2max
Maximal oxygen uptake
- VO2peak
Peak oxygen uptake
- VTA
Ventral tegmental area
- WADA
World Anti‐Doping Agency
- WHO
World Health Organization
- XC‐Ski
Cross‐country skiing
Funding
No specific funding was received for this research. Open access funding was enabled and organized by Projekt DEAL.
Ethics Statement
The author has nothing to report.
Conflicts of Interest
The author declares no conflicts of interest.
Supporting Information
Additional supporting information can be found online in the Supporting Information section.
Supporting information
Supporting Information The Supporting Information comprises a six‐section narrative (S1–S6) providing extended evidence underlying the main manuscript: pharmacological profiles (S1), consumption phenotype definitions (S2), extended organ‐specific safety evidence (S3), sport‐specific decision framework (S4), COX‐selectivity of analgesics (S5), and the cause–effect arc of analgesic self‐medication (S6). Table S1. Pharmacological profile of NSAIDs and related analgesics relevant to endurance sport, summarizing active substance, drug class, mechanism, COX selectivity, half‐life, over‐the‐counter dose limits, and clinical notes for ibuprofen, diclofenac, naproxen, acetylsalicylic acid, paracetamol, and prescription‐only agents (etoricoxib, celecoxib, metamizole, indomethacin, and ketoprofen). Figure S1. COX‐selectivity of analgesics relevant to endurance sport, displayed as a horizontal logarithmic IC80 COX‐2/COX‐1 ratio bar chart based on published whole‐blood assay data, with elimination half‐life and OTC dose limits annotated for each agent. Figure S2. Seven‐stage cause–effect arc of analgesic self‐medication in endurance sport, tracing the athlete’s pathway from training load through overuse injury, pain, cognitive appraisal, decision, self‐medication, and consequences, with the pharmacist checkpoint and the self‐perpetuating feedback loop highlighted.
Acknowledgments
Declaration of Generative AI and AI-Assisted Technologies in the Writing Process. Final text revision, structural editing, citation standardization, and proofreading were performed with the assistance of Claude (Anthropic). The author provided all scientific content, made all substantive decisions regarding study selection, evidence interpretation, and clinical conclusions and takes full responsibility for the accuracy and integrity of the work.
Will, Andreas , The Convergent Renal Insult: Why Endurance Athletes’ Self‐Medication With Nonsteroidal Anti‐Inflammatory Drugs Requires a Sport‐Specific Risk Model—A Narrative Review From Pharmaceutical and Sport‐Science Perspectives, Translational Sports Medicine, 2026, 8716858, 12 pages, 2026. 10.1155/tsm2/8716858
Academic Editor: Shashank Kaushik
Contributor Information
Andreas Will, Email: andreas.x.will@tum.de.
Shashank Kaushik, Email: shkaushik@wiley.com.
Data Availability Statement
Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.
References
- 1. Gjelstad A., Herlofsen T. M., Bjerke A.-L., Lauritzen F., and Björnsdottir I., Use of Pharmaceuticals Amongst Athletes Tested by Anti-Doping Norway in a five-year Period, Frontiers in Sports and Active Living. (2023) 5, 10.3389/fspor.2023.1260806. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Pannone E. and Abbott R., What is Known About the Health Effects of NSAID Use in Marathon and Ultraendurance Running: a Scoping Review, BMJ Open Sport Exerc Med. (2024) 10, no. 1, 10.1136/bmjsem-2023-001846. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Leyk D., Rüther T., Hartmann N., Vits E., Staudt M., and Hoffmann M. A., Analgesic Use in Sports, Results of a Systematic Literature Review, Deutsches Ärzteblatt International. (2023) 120, 155–161, 10.3238/arztebl.m2023.0003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Cole P. L., Bontemps B., Pugh J., and Owens D. J., The Prevalence and Perceptions of Non-Steroidal Anti-Inflammatory Drug Use Among Ultra-Endurance Runners, Research in Sports Medicine. (2025) 34, no. 3, 257–275, 10.1080/15438627.2025.2561040. [DOI] [PubMed] [Google Scholar]
- 5. Dietz P., Dalaker R., Letzel S. et al., Analgesics Use in Competitive Triathletes, Journal of Sports Sciences. (2016) 34, no. 20, 1965–1969, 10.1080/02640414.2016.1149214. [DOI] [PubMed] [Google Scholar]
- 6. Küster M., Renner B., Oppel P., Niederweis U., and Brune K., Consumption of Analgesics Before a Marathon and the Incidence of Cardiovascular, Gastrointestinal and Renal Problems, BMJ Open. (2013) 3, no. 4, 10.1136/bmjopen-2012-002090. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Lipman G. S., Shea K., Christensen M. et al., Ibuprofen Versus Placebo Effect on Acute Kidney Injury in Ultramarathons: a Randomized Controlled Trial, Emergency Medicine Journal. (2017) 34, no. 10, 637–642, 10.1136/emermed-2016-206353. [DOI] [PubMed] [Google Scholar]
- 8. Gorski T., Cadore E. L., Pinto S. S. et al., Use of NSAIDs in Triathletes: Prevalence, Level of Awareness and Reasons for Use, British Journal of Sports Medicine. (2011) 45, no. 2, 85–90, 10.1136/bjsm.2009.062166. [DOI] [PubMed] [Google Scholar]
- 9. Robach P., Trebes G., Buisson C. et al., Prevalence of Drug Use in Ultraendurance Athletes, Medicine & Science in Sports & Exercise. (2024) 56, no. 5, 828–838, 10.1249/MSS.0000000000003374. [DOI] [PubMed] [Google Scholar]
- 10. Fitzpatrick D., Leckie T., Heine G., and Hodgson L., The Use of Pain Killers (NSAIDs) in Athletes: How Large is the Risk?, Journal of Science and Medicine in Sport. (2025) 28, no. 3, 198–205, 10.1016/j.jsams.2024.11.010. [DOI] [PubMed] [Google Scholar]
- 11. Warner D. C., Schnepf G., Barrett M. S. et al., Prevalence, Attitudes, and Behaviors Related to NSAIDs in Student Athletes, Journal of Adolescent Health. (2002) 30, no. 3, 150–153, 10.1016/S1054-139X(01)00325-1. [DOI] [PubMed] [Google Scholar]
- 12. Calatayud S. and Esplugues J. V., Lanas A., Chemistry, Pharmacodynamics, and Pharmacokinetics of NSAIDs, NSAIDs and Aspirin, 2016, Springer, 3–16, 10.1007/978-3-319-33889-7_1. [DOI] [Google Scholar]
- 13. Lundberg T. R. and Howatson G., Analgesic and Anti-inflammatory Drugs in Sports, Scandinavian Journal of Medicine & Science in Sports. (2018) 28, no. 11, 2252–2262, 10.1111/sms.13275. [DOI] [PubMed] [Google Scholar]
- 14. Mallinson J. E., Taylor T., Constantin‐Teodosiu D. et al., NSAID Ingestion Augments training-induced Muscle Hypertrophy and Differentially Affects Muscle mRNA Expression, but Not Strength Gains, in Trained Men, The Journal of Physiology. (2025) 10.1113/JP289542. [DOI] [PubMed] [Google Scholar]
- 15. Warner T. D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J. A., and Vane J. R., Nonsteroid Drug Selectivities for COX-1 Rather than COX-2 are Associated with Human Gastrointestinal Toxicity, Proceedings of the National Academy of Sciences of the United States of America. (1999) 96, no. 13, 7563–7568, 10.1073/pnas.96.13.7563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Hinz B. and Brune K., Paracetamol and Cyclooxygenase Inhibition: Is there a Cause for Concern?, Annals of the Rheumatic Diseases. (2012) 71, no. 1, 20–25, 10.1136/ard.2011.200087. [DOI] [PubMed] [Google Scholar]
- 17. Lazarus R. S., How Emotions Influence Performance in Competitive Sports, The Sport Psychologist. (2000) 14, no. 3, 229–252, 10.1123/tsp.14.3.229. [DOI] [Google Scholar]
- 18. Lazarus R. S. and Folkman S., Stress, Appraisal, and Coping, 1984, Springer, New York. [Google Scholar]
- 19. Melzer M., Elbe A.-M., and Strahler K., Athletes’ Use of Analgesics is Related to Doping Attitudes, Competitive Anxiety, and Situational Opportunity, Frontiers in Sports and Active Living. (2022) 4, 10.3389/fspor.2022.849117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Navratilova E., Atcherley C., and Porreca F., Brain Circuits Encoding Reward from Pain Relief, Trends in Neurosciences. (2015) 38, no. 11, 741–750, 10.1016/j.tins.2015.09.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Cullen G., Kelly E., and Murray F. E., Patients’ Knowledge of Adverse Reactions to Current Medications, British Journal of Clinical Pharmacology. (2006) 62, no. 2, 232–236, 10.1111/j.1365-2125.2006.02642.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Mullan J., Weston K. M., Bonney A., Burns P., and Rudd R., Consumer Knowledge About over-the-counter NSAIDs: They Don’t Know What They Don’t Know, Australian & New Zealand Journal of Public Health. (2017) 41, no. 2, 135–140, 10.1111/1753-6405.12617. [DOI] [PubMed] [Google Scholar]
- 23. Poortmans J. R., Exercise and Renal Function, Sports Medicine. (1984) 1, no. 2, 125–153, 10.2165/00007256-198401020-00003. [DOI] [PubMed] [Google Scholar]
- 24. Thomas M. C., Diuretics, ACE Inhibitors and NSAIDs, the Triple Whammy, Medical Journal of Australia. (2000) 172, no. 4, 184–185, 10.5694/j.1326-5377.2000.tb125548.x. [DOI] [PubMed] [Google Scholar]
- 25. Harężlak T., Religioni U., Szymański F. M. et al., Drug Interactions Affecting Kidney Function: Beware of Health Threats from Triple Whammy, Advances in Therapy. (2022) 39, no. 1, 140–147, 10.1007/s12325-021-01939-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Dreischulte T., Morales D. R., Bell S., and Guthrie B., Combined Use of Nonsteroidal Anti-Inflammatory Drugs With Diuretics and/or Renin–Angiotensin System Inhibitors in the Community Increases the Risk of Acute Kidney Injury, Kidney International. (2015) 88, no. 2, 396–403, 10.1038/ki.2015.101. [DOI] [PubMed] [Google Scholar]
- 27. Specht J. W., Bailly A. R., Garcia S. et al., Effect of Ibuprofen on Markers of Acute Kidney Injury, Intestinal Injury, and Endotoxemia After Running in the Heat, Medicine & Science in Sports & Exercise. (2025) 57, no. 6, 1092–1102, 10.1249/MSS.0000000000003625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Wharam P. C., Speedy D. B., Noakes T. D., Thompson J. M., Reid S. A., and Holtzhausen L. M., NSAID Use Increases the Risk of Developing Hyponatremia During an Ironman Triathlon, Medicine & Science in Sports & Exercise. (2006) 38, no. 4, 618–622, 10.1249/01.mss.0000210209.40694.09. [DOI] [PubMed] [Google Scholar]
- 29. Poussel M., Touzé C., Allado E. et al., Ultramarathon and Renal Function: Does exercise-induced AKI Really Exist in Common Conditions?, Frontiers in Sports and Active Living. (2020) 1, 10.3389/fspor.2019.00071. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Wołyniec W., Kasprowicz K., Giebułtowicz J. et al., Changes in water-soluble Uremic Toxins and Urinary AKI Biomarkers After 10- and 100-km Runs, International Journal of Environmental Research and Public Health. (2019) 16, no. 21, 10.3390/ijerph16214153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Mansour S. G., Verma G., Pata R. W., Martin T. G., Perazella M. A., and Parikh C. R., Kidney Injury and Repair Biomarkers in Marathon Runners, American Journal of Kidney Diseases. (2017) 70, no. 2, 252–261, 10.1053/j.ajkd.2017.01.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Soliman S., Ahmed R. M., Ahmed M. M., Attia A., and Soliman A. R., NSAIDs: what is the Actual Risk of Chronic Kidney Disease? A Systematic Review and meta-analysis, Romanian Journal of Internal Medicine. (2025) 63, no. 1, 3–27, 10.2478/rjim-2024-0029. [DOI] [PubMed] [Google Scholar]
- 33. Coca S. G., Singanamala S., and Parikh C. R., Chronic Kidney Disease After Acute Kidney Injury: a Systematic Review and meta-analysis, Kidney International. (2012) 81, no. 5, 442–448, 10.1038/ki.2011.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Glaser J., Lemery J., Rajagopalan B. et al., Climate Change and the Emergent Epidemic of CKD from Heat Stress, Clinical Journal of the American Society of Nephrology. (2016) 11, no. 8, 1472–1483, 10.2215/CJN.13841215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. van Wijck K., Lenaerts K., Van Bijnen A. A. et al., Aggravation of exercise-induced Intestinal Injury by Ibuprofen in Athletes, Medicine & Science in Sports & Exercise. (2012) 44, no. 12, 2257–2262, 10.1249/MSS.0b013e318265dd3d. [DOI] [PubMed] [Google Scholar]
- 36. Bhala N., Emberson J., Merhi A. et al., Vascular and Upper Gastrointestinal Effects of NSAIDs: Meta-Analyses of Individual Participant Data, Lancet. (2013) 382, no. 9894, 769–779, 10.1016/S0140-6736(13)60900-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Trappe T. A., White F., Lambert C. P., Cesar D., Hellerstein M., and Evans W. J., Effect of Ibuprofen and Acetaminophen on Postexercise Muscle Protein Synthesis, American Journal of Physiology. (2002) 282, no. 3, E551–E556, 10.1152/ajpendo.00352.2001. [DOI] [PubMed] [Google Scholar]
- 38. Lilja M., Mandić M., Apró W. et al., High Doses of Anti-inflammatory Drugs Compromise Muscle Strength and Hypertrophic Adaptations to Resistance Training in Young Adults, Acta Physiologica. (2018) 222, no. 2, 10.1111/apha.12948. [DOI] [PubMed] [Google Scholar]
- 39. Trappe T. A., Carroll C. C., Dickinson J. M. et al., Influence of Acetaminophen and Ibuprofen on Skeletal Muscle Adaptations to Resistance Exercise in Older Adults, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. (2011) 300, no. 3, R655–R662, 10.1152/ajpregu.00611.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Christensen B., Dandanell S., Kjaer M., and Langberg H., Effect of Anti-inflammatory Medication on the running-induced Rise in Patella Tendon Collagen Synthesis, Journal of Applied Physiology. (2011) 110, no. 1, 137–141, 10.1152/japplphysiol.00942.2010. [DOI] [PubMed] [Google Scholar]
- 41. Cornu C., Grange C., Regalin A. et al., Effect of Non-steroidal Anti-inflammatory Drugs on Sport Performance Indices in Healthy People: a meta-analysis of Randomized Controlled Trials, Sports Medicine-Open. (2020) 6, no. 1, 10.1186/s40798-020-00247-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Grgic J. and Mikulic P., Effects of Paracetamol Ingestion on Endurance Performance: Systematic Review and meta-analysis, Sports. (2021) 9, no. 9, 10.3390/sports9090126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. KDIGO CKD Work Group, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney International Supplements. (2013) 3, no. 1, 1–150, 10.1038/kisup.2012.73. [DOI] [PubMed] [Google Scholar]
- 44. KDIGO CKD Work Group, KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney International. (2024) 105, no. 4S, S117–S314, 10.1016/j.kint.2023.10.018. [DOI] [PubMed] [Google Scholar]
- 45. KDIGO AKI Work Group, KDIGO Clinical Practice Guideline for Acute Kidney Injury, Kidney International Supplements. (2012) 2, no. 1, 1–138, 10.1159/000339789. [DOI] [Google Scholar]
- 46. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM), Deutsche Gesellschaft für Nephrologie (DGfN), S3-Leitlinie: Versorgung von Patient∗innen mit Chronischer, Nicht-Nierenersatztherapiepflichtiger Nierenkrankheit in der Hausarztpraxis (Update 2024), AWMF-Reg.-Nr. 053-048, DEGAM-Leitlinie Nr. 22, 2024, https://register.awmf.org/de/leitlinien/detail/053-048.
- 47. Sawka M. N., Burke L. M., Eichner E. R. et al., American College of Sports Medicine Position Stand. Exercise and Fluid Replacement, Medicine & Science in Sports & Exercise. (2007) 39, no. 2, 377–390, 10.1249/mss.0b013e31802ca597. [DOI] [PubMed] [Google Scholar]
- 48. Hainline B., Derman W., Vernec A. et al., IOC Consensus Statement on Pain Management in Elite Athletes, British Journal of Sports Medicine. (2017) 51, no. 17, 1245–1258, 10.1136/bjsports-2017-097884. [DOI] [PubMed] [Google Scholar]
- 49. Seiberth J. M., Moritz K., Küçükay N. et al., Information Exchange During self-medication Counseling in German Community Pharmacies, PLoS One. (2020) 15, no. 10, 10.1371/journal.pone.0240672. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Kelly W. N., Ho M. J., Smith T., Bullers K., Bates D. W., and Kumar A., Association of Pharmacist Interventions with Adverse Drug Events and Potential Adverse Drug Events, Pharmacoepidemiology and Drug Safety. (2024) 33, no. 7, 10.1002/pds.5853. [DOI] [PubMed] [Google Scholar]
- 51. Dreischulte T., Donnan P., Grant A., Hapca A., McCowan C., and Guthrie B., Safer Prescribing: a Trial of Education, Informatics, and Financial Incentives, New England Journal of Medicine. (2016) 374, no. 11, 1053–1064, 10.1056/NEJMsa1508955. [DOI] [PubMed] [Google Scholar]
- 52. Bundesvereinigung Deutscher Apothekerverbände e. V. (ABDA), Arbeitshilfe zur Qualitätssicherung: Information und Beratung im Rahmen der Selbstmedikation am Beispiel Kopfschmerzen, 2025, https://www.abda.de/fileadmin/user_upload/assets/Praktische_Hilfen/Leitlinien/Selbstmedikation/AWB_SM_Kopfschmerzen.pdf.
- 53. Hoffman M. D. and Weiss R. H., Does Acute Kidney Injury from an Ultramarathon Increase the Risk for Greater Subsequent Injury?, Clinical Journal of Sport Medicine. (2016) 26, no. 5, 417–422, 10.1097/JSM.0000000000000277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Juett L. A., Funnell M. P., Carroll H. A., James L. J., and Mears S. A., 24 h Severe Fluid Restriction Increases a Biomarker of Renal Injury in Healthy Males, European Journal of Applied Physiology. (2025) 125, no. 7, 1983–1995, 10.1007/s00421-025-05749-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supporting Information The Supporting Information comprises a six‐section narrative (S1–S6) providing extended evidence underlying the main manuscript: pharmacological profiles (S1), consumption phenotype definitions (S2), extended organ‐specific safety evidence (S3), sport‐specific decision framework (S4), COX‐selectivity of analgesics (S5), and the cause–effect arc of analgesic self‐medication (S6). Table S1. Pharmacological profile of NSAIDs and related analgesics relevant to endurance sport, summarizing active substance, drug class, mechanism, COX selectivity, half‐life, over‐the‐counter dose limits, and clinical notes for ibuprofen, diclofenac, naproxen, acetylsalicylic acid, paracetamol, and prescription‐only agents (etoricoxib, celecoxib, metamizole, indomethacin, and ketoprofen). Figure S1. COX‐selectivity of analgesics relevant to endurance sport, displayed as a horizontal logarithmic IC80 COX‐2/COX‐1 ratio bar chart based on published whole‐blood assay data, with elimination half‐life and OTC dose limits annotated for each agent. Figure S2. Seven‐stage cause–effect arc of analgesic self‐medication in endurance sport, tracing the athlete’s pathway from training load through overuse injury, pain, cognitive appraisal, decision, self‐medication, and consequences, with the pharmacist checkpoint and the self‐perpetuating feedback loop highlighted.
Data Availability Statement
Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.
